tbuckley/cabot-search huggingface dataset:
Does vascular imaging with MRI predict response to neoadjuvant chemotherapy in primary breast cancer?
Authors: M.-L. W. Ah-See, A. Makris, N. J. Taylor, R. J. Burcombe, M. Harrison, J. J. Stirling, P. I. Richman, M. O. Leach, A. R. Padhani
Journal: Journal of Clinical Oncology (2004)

582 Background: The ability to identify early during treatment those women with primary breast cancer (PBC) who will fail to respond to neoadjuvant chemotherapy will enable the use of alternative therapies that may be more effective. Here, we assess the role of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to identify the non-responders. Methods: 28 patients with PBC (median age 46 years; range 29–70) were imaged prior to & following 2 cycles of 5-fluorouracil, epirubicin & cyclophosphamide (FEC) NAC. DCE-MRI scans were obtained following Gd-DTPA contrast medium using T1 & T2* weighted techniques with derivation of parametric images that reflected tissue microvessel permeability, leakage space & perfusion (Ktrans, ve, kep, MaxGd, rBV, rBF & MTT). Median & 5–95th centile values for each parameter were derived from whole tumour regions of interest. Pre-treatment parameter values & treatment changes were correlated with clinical & pathological response following 6 cycles of NAC using the Mann-Whitney U-test. A cohort of 9 patients was imaged twice prior to therapy to calculate the repeatability statistic for each parameter & hence determine the ability of DCE-MRI to predict pathological non-response on a patient-by-patient basis. Results: There were 19 clinical responders & 9 clinical non-responders; 11 pathological responders & 17 pathological non-responders. Pre-treatment parameter values & change in tumour size did not predict for response. Group analysis showed that changes in median Ktrans, kep, rBV & rBF correlated with both final clinical & pathological response to NAC (p<0.005 & p<0.01 respectively) as did changes in 5–95th centile range for these parameters (p<0.05). Application of the repeatability statistic revealed change in median Ktrans to be the best predictor of pathological non-response in individuals (repeatability range -49 to 97%) correctly predicting pathological non-response in all 17 patients (100%) & response in 6/11 patients (55%). Conclusion: Patients who are destined to fail to respond to NAC can be identified from early changes in DCE-MRI parameters that reflect on microvessel perfusion & permeability. No significant financial relationships to disclose.
Impact of BCR Stimulation on Mir-181b in Chronic Lymphocityc Leukemia
Authors: Amerigo Mirco Di Marco, Francesco Autore, Paola Lanuti, Idanna Innocenti, Giuseppe Leone, Alice Ramassone, Angelo Veronese, Renato Mariani Costantini, Luca Laurenti, Rosa Visone
Journal: Blood (2016)
THE INCREASING BURDEN OF AMYLOIDOSIS FROM APEX TO BASE: NEW INSIGHTS FROM TECHNETIUM-99M PYROPHOSPHATE IMAGING
Authors: Scott Ray, Khan Aahad, Sharmeen Hussaini, Syed Haris A. Pir, Mustafa Noor Muhammad, Mirza Nubair Ahmad, Debra Mahlum, Steven C. Port, A. Jamil Tajik, Khawaja Afzal Ammar
Journal: Journal of the American College of Cardiology (2017)
Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML).
Authors: Olivier Nibourel, Olivier Kosmider, Meyling Cheok, Nicolas Boissel, Aline Renneville, Nathalie Philippe, Hervé Dombret, Francois Dreyfus, Bruno Quesnel, Sandrine Geffroy, Samuel Quentin, Catherine Roche-Lestienne, Jean-Michel Cayuela, Christophe Roumier, Pierre Fenaux, William Vainchenker, Olivier A Bernard, Jean Soulier, Michaela Fontenay, Claude Preudhomme
Journal: Blood (2009)
Survival of patients (pts) with advanced lung adenocarcinoma (ALA) treated in four hospitals from Bogotá D.C., Colombia, and report of a novel alteration in the epidermal growth factor receptor (EGFR) (ONCOLGroup study)
Authors: J. M. Otero, A. F. Cardona, E. Carrasco-Chaumel, H. Carranza, C. Vargas, C. Carlos, T. Diana, R. Ludovic, N. Reguart, M. Cuello
Journal: Journal of Clinical Oncology (2009)

e19097 Background: This study included 147 ALA pts treated between 2000 and 2007. Overall response rates (ORR), clinical benefit (CB), time to progression (TTP) and overall survival (OS) were estimated. EGFR E19 deletions were studied by length analysis fluorescently and the exon 21 L858R mutation by PCR Taqman assay. Results: Mean age was 66±12.8 years. Seventy- eight pts were women, 40% had never been exposed to tobacco smoke and PS was ≥70% in 119 pts. The brain was the dominant site for metastasis (38%) followed by the lungs (38%). Sixty-nine percent of the pts received a platinum doublet as first-line intervention and 32 pts (21.8%) had received erlotinib (E) as part of their treatment. Response to first-line treatment was available in 110 pts; ORR was 28%, CB 39% and TTP 4.2 mo. (range, 0.2–11). Second-line therapy was administered to 46 pts; ORR was 8%, CB 25% and TTP 3.7 mo. (range, 0.4–12). Twenty pts received third-line therapy, with an ORR of 35%, CB 50% and a TTP 3.9 mo. (range, 1.0–5.7). Median OS was 10.1 mo. (range, 6.3–19) and the PS, absence of tobacco exposure, and administration of E, positively influenced this outcome. EGFR mutational profile was assessed in 6 pts; 3 pts presented mutations in E19, one a 5-nucleotide deletion (E746_A750) and 2 pts had a 3 serine-rich nucleotide insertion (L747_S75) which has not been previously reported. The first patient had a partial response, and the last two, had survival greater than 16-mo. Conclusions: Outcomes for pts suffering from ALA in Colombia are similar to those described in other Latin American countries. Three pts with EGFR alterations were identified in this cohort; two presented a non- described change in E19 which may have corresponded to a novel alteration in our region, with possible increased sensitivity to E. No significant financial relationships to disclose.
Comparative analysis of bone marrow micrometastases with sentinel lymph node status in early-stage breast cancer.
Authors: Madan L. Arora, Shams Mistry, Mohammed Shaik, Neha Tyagi, Alpesh K. Korant, Supriya Kumar Saha, Gregory Johnston, Benjamin Abadeer, Vikrom K. Dhar, David Wiese, Sukamal Saha
Journal: Journal of Clinical Oncology (2013)

570 Background: A definitive relationship between bone marrow (BM) micrometastases (M) and sentinel lymph node (SLN) status has not been established in Breast Cancer (BRCa). Hence, a retrospective study was done to examine the relationship between BMM and SLN status in BRCa patients (pts). Methods: T1/T2 BRCa pts underwent SLN biopsy and definitive surgery for primary tumors. At the operation, BM aspiration from bilateral post-superior iliac spines was performed. BM samples were examined using a Cytokeratin Detection Kit using CAM 5.2 monoclonal antibody and visualization achieved with a Ventana iView V-Red detection system. An Automated Cellular Imaging System was applied to identify metastatic BRCa cells. Pts with +ve BM underwent repeat BM analysis 6 months after completing initial treatments. Data was collected for T-stages, SLN, BM, ER/PR receptor and Her-2/neu statuses and analyzed using Chi-Square Analysis or Fischer’s Exact Test. Results: We analyzed 458 consecutive pts, of which SLN metastasesv(mets) were detected in 22.9% and BMM were detected in 8.1%. BMM were found 23% bilaterally and 77% unilaterally. BMM were detected in 11.4% of SLN +ve pts versus 7.1% of SLN -ve ptsv(p=0.15) and 6.8% of T1 pts versus 12.3% of T2 ptsvv(p=0.07). BMM were found in 8.7% of ER/PR +ve pts versus 4.5% of ER/PR –ve ptsvv(p=0.1) and 9.5% of HER2/neu +ve pts versus 7.7% of HER2/neu –ve ptsv (p=0.5) (Table). Repeat BM analysis detected BMM only in 6.6% pts. Conclusions: Bilateral BM aspirate resulted in a significant increase in detection of micrometastases. BM metastases may occur independently of lymphatic metastasis. Therefore, evaluation for the presence of BMM may help identify high risk pts with node negative disease in early stage BRCa. [Table: see text]
IMPACT OF MALIGNANT LEFT VENTRICULAR FUNCTION ON INCIDENT HEART FAILURE WITH REDUCED VERSUS PRESERVED EJECTION FRACTION: THE MESA STUDY
Authors: Matthew N. Peters, Stephen Seliger, Susie Hong-Zohlman, James de Lemos, Joao Lima, Lori Daniels, Robert Christenson, Alain Bertoni, Christopher DeFilippi
Journal: Journal of the American College of Cardiology (2017)
ELECTRICAL STORM IN CHAGAS HEART DISEASE PATIENTS WITH IMPLANTABLE CARDIOVERTER DEFIBRILLATOR – CLINICAL PREDICTORS, OUTCOME AND ARRHYTHMIC CHARACTERISTICS: A PROSPECTIVE REGISTRY FROM A UNIVERSITY HOSPITAL
Authors: Maria Licia Pavao, Elerson Arfelli, Adilson Scorzoni Filho, Rafael Brolio Pavao, Antonio Pazin Filho, Jose Antonio Marin Neto, Andre Schmidt
Journal: Journal of the American College of Cardiology (2017)
COMPARISON BETWEEN ANGIOSCOPIC AND OPTICAL COHERENCE TOMOGRAPHIC ASSESSMENT OF INSTENT RESTENOSIS
Authors: Junji Mastuda, Taishi Yonetsu, Tadashi Murai, Yoshihisa Kanaji, Eisuke Usui, Makoto Araki, Takayuki Niida, Rikuta Hamaya, Tsunekazu Kakuta
Journal: Journal of the American College of Cardiology (2017)
The effect of platinum based adjuvant chemotherapy on survival in the surgically resected lung adenocarcinoma according to the expression of EGFR mutation specific antibody and c-MET.
Authors: In-Ho Kim, Jieun Lee, Sujung Kim, Ho Jung An, Sang Hoon Chun, Eun Kyoung Jeon, Sook Hee Hong, Tae-Jung Kim, Kyo Young Lee, Sook-Whan Sung, Jae Gil Park, Seungjoon Kim, Young Kyoon Kim, Jeong-Oh Kim, Jin Hyoung Kang
Journal: Journal of Clinical Oncology (2015)

7523 Background: To assess the role of mutant EGFR and C-MET in survival benefit obtained from platinum-based adjuvant chemotherapy (PBAC) among resected lung adenocarcinoma (RLADC) patients. Methods: From 2005 through 2013, the RLADC patients (stage IB-IIIA) receiving either PBAC (Paclitaxel/Carboplatin, Paclitaxel/Cisplatin, or Vinorelbine/Cisplatin) or to be observed were enrolled. We did immunohistochemistry (IHC) study with mutant EGFR-specific antibody (mutEGFR-sAb) and C-MET in tissue microarray with 301 cases. We assessed the effect of PBAC on survival according to the expression of mutEGFR-sAb and C-MET. Results: Until Oct. 2014, 85 patients experienced relapse and 65 patients died among 301 patients. The median follow-up period for survival was 22.4 months. 137 patients received PBAC. Clinical characteristics is as follows; F: M = 165:136, stage Ib 170, II 74, IIIa 47. The IHC were positive for mutEGFR-sAb in 78 cases (42 in exon 19, 36 in exon 21) and for C-MET in 136 cases. Compared with EGFR mutation by direct sequencing ,the specificity and sensitivity of mutEGFR-sAb were 99% and 88%, respectively. PBAC prolonged overall survival (OS) in mutEGFR-sAb (+) group of stage II,III patients with statistical significance (p = .040), not in mutEGFR-sAb (-) group (p = .460). Among all patients, PBAC was an independent prognostic factor for relapse free survival(RFS) (HR = 0.29, P = .034) and OS (HR = 0.17, P = .033) in mutEGFR-sAb (+) group. By contrast, in patients with mutEGFR-sAb (-), PBAC was not associated with RFS (HR = 0.63, p = .144) and OS (HR = 0.55, P = .091). Meanwhile, in C-MET (+) subgroup of stage II and IIIa patients, PBAC showed significantly longer survival (RFS; p = .088, OS; p = .015), not in C-MET (-) subgroup. (RFS; p = .979, OS; p = .839). The multivariate analysis indicated that PBAC may be an important factor for increased survival among C-MET(+) patients (RFS; HR = 0.53, p = .086, OS; HR = 0.34, p = .010) but not among C-MET (-) (RFS; HR = 0.74, p = .472, OS; HR = 0.77, p = .597). Conclusions: Taken together, our data suggests that overexpression of mutEGFR-sAb and C-MET may be favorable predictive biomarkers for PBAC among RLADC patients.
<i>Helicobacter pylori</i>-independent MALT lymphoma patients responsive to thalidomide—the molecular mechanism and the clinical application
Authors: S. Kuo, L. Chen, M. Wu, C. Hsu, C. Lin, P. Hsu, K. Yeh, Y. Tzeng, A. Cheng
Journal: Journal of Clinical Oncology (2009)

e19512 Background: We have recently demonstrated that nuclear expression of BCL10 or NF-κB helps predict H. pylori-independent status; and inflammatory cytokines such as TNF-α may be related to BCL10 nuclear translocation (Blood 2005;106:1037–41;J Biol Chem 2006;281:167–75). Recent studies have been shown that the chimeric protein of t(11;18)(q21;q21) can lead to constitutive NF-κB activity and thereby mediate cell survival and anti-apoptotic signals. The present study was conducted to investigate the molecular mechanism and the clinical efficacy of thalidomide, an TNF-α or NF-κB inhibitor, in H. pylori-independent MALT lymphoma. Methods: Between October 2003 and June 2007, our study enrolled 11 H. pylori-independent MALT lymphoma patients ( 7 men and 4 women; age range, 43 to 79 years; 7 patients who had failed chemotherapy or rituximab) with nuclear expression of BCL10 or NF-κB in pretreatment lymphoma tissues treated at National Taiwan University Hospital with thalidomide 100mg to 200 mg oral given daily. The presence of t(11;18)(q21;q21) was identified by a multiplex reverse transcriptase polymerase chain reaction of the API2-MALT1 chimeric transcript. Results: Three (27.3%) of 11 patients achieved a complete response (CR), and 3 (27.3) of 11 patients achieved a partial response (PR), resulting in an overall response rate of 54.5% (95% CI, 19.5%-89.6%). The median time from thalidomide therapy to CR was 3.0 months (range, 2.7–4.9 months). At a median follow-up of 41.6 months (range, 17.7–63.8 months), the 3-year event-free survival and overall survival after thalidomide treatment was 80.8%, and 88.9%, respectively. The API2-MALT1 fusion transcript for t(11;18)(q21;q21) was detected in 1 (16.7%) of 6 patients with CR or PR, and 4 (80.0%) of 5 patients with stable or progressive disease (P = 0.08). Conclusions: Our results indicate that thalidomide can be an adjuvant treatment for H. pylori-independent MALT lymphoma patients. Additional investigation of the molecular mechanisms and biologic significance of the API2-MALT1 fusion transcript responsible for thalidomide resistance in this group of tumors is needed. No significant financial relationships to disclose.
DOES PRESENCE OF ATRIAL FIBRILLATION AFFECT IN-HOSPITAL MORTALITY IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION? RESULTS FROM A REAL-WORLD REGISTRY
Authors: Gaurav Patel, Maitri Pancholy, Sukrut Nanavaty, Neha Pancholy, Aman Patel, Anvit Rai, John Coppola, Tak Kwan, Tejas Patel, Samir Pancholy
Journal: Journal of the American College of Cardiology (2017)
COMPARISON OF THE NOVEL METHOD VERSUS THE FRIEDEWALD EQUATION IN ESTIMATING LOW-DENSITY LIPOPROTEIN-CHOLESTEROL BASED ON FASTING STATUS
Authors: Vasanth Sathiyakumar, Asieh Golozar, Mariana Lazo, Renato Quispe, Eliseo Guallar, Roger Blumenthal, Steven Jones, Seth Martin
Journal: Journal of the American College of Cardiology (2017)
LOW DIETARY SODIUM INTAKE IS ASSOCIATED WITH LOW ENERGY INTAKE AND DIETARY MICRONUTRIENT DEFICIENCY IN ELDERLY PATIENTS HOSPITALIZED FOR HEART FAILURE
Authors: Scott L. Hummel, Wahida Karamally, Omar Jimenez, Maria L. Cornellier, Erika Trumble, Jeffrey Wessler, Mathew Maurer
Journal: Journal of the American College of Cardiology (2017)
Transition of follow-up care to primary care physicians (PCPs) of breast cancer (BC) survivors: Barriers and patient satisfaction.
Authors: Melini Gupta, Carol A. Townsley, Ed Kucharski, Rashida Haq, Linda Muraca, Susan Blacker, Shari Moura, Ralph L. George, Pamela Catton, Terri Stuart-McEwan, Christine Elser
Journal: Journal of Clinical Oncology (2015)

e20613 Background: The number ofBC survivorsis increasing due to changing demographics and improved outcomes, putting pressure on cancer programs. Cancer Care Ontario has released clinical guidelines endorsing the role of the PCPs in well follow-up care of BC survivors and calling on Regional Cancer Programs to implement new models of care. This study aims to assess (i) provider barriers for early transition of care and (ii) patient satisfaction with a pilot transfer process. Methods: A cross-sectional survey was sent to all oncologists (n = 23) and PCPs (n = 300) practicing in the Toronto South Central LHIN. Questions included practice patterns, attitudes toward early transfer (oncologists), experience with- and readiness for BC patients, and educational needs (PCPs). The pilot study included patients followed for > 2 years after treatment, they received a treatment summary and informative pamphlet, saw their PCP within 4-6 weeks and were surveyed regarding acceptability and feasibility of this strategy. Results: 15 oncologists (66%) answered. Most follow patients for 5 years (78%). Medical oncologists discharge many patients after 2-3y (55%) if they are not on hormone therapy (HT). Most important barriers to early discharge are inability to discuss extended HT (67%), PCP inexperience with side effects from HT (60%) while multiple other factors contribute to decision making. 62 PCPs responded (21%), of these 82% provide care after patients are discharged from specialists and the majority is comfortable managing symptoms such as fatigue, memory loss, sexual, and psychosocial health (69/55/61/75%) with the exception of vaginal bleeding (33%). However, more than 80% would like additional support on care for BC survivors. Following the pilot transfer, patients felt well prepared by their oncologist and confident in their PCP’s ability to provide follow-up care. Conclusions: Most responding PCPs are prepared to care for BC survivors after early discharge but desire additional educational support. Patients are comfortable with early transition. However, in a context of increasingly complex adjuvant HT options oncologists are concerned about optimal management after discharge.
Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.
Authors: Harriet M. Kluger, Susan Halabi, Nicole C Solomon, Lucia Jilaveanu, Christopher Zito, Joshua Sznol, Andrew B. Nixon, Brian I. Rini, Eric Jay Small, Daniel J. George
Journal: Journal of Clinical Oncology (2014)

4532 Background: In CALGB 90206, a phase III trial of IFN +/- Bev, the addition of Bev was associated with an improved progression-free survival (PFS) in RCC pts. Previously, we assessed a panel of soluble cytokines and angiogenic factors and demonstrated that IL-6 and HGF were predictive of overall survival (OS) from Bev. The objective was to evaluate the prognostic importance of tissue expression levels of cytokines and angiogenic factors in pre-treatment specimens from CALGB 90206 pts and to test whether they interacted with the treatment arm in predicting OS and PFS. Methods: Tissue microarrays were constructed using 3 cores from pretreatment specimens from 220 patients and stained for VEGFR1-3, VEGF A, B, C and D, HGF, c-Met, IL-6, IL-6R and STAT3 using a method of quantitative immunofluorescence. Vessel density was quantified by area of CD-34 staining. The proportional hazards model was used to test for the prognostic importance of marker levels (prognostic factors) and whether they interacted with the treatment arm (predictive factors) in predicting OS and PFS using prior nephrectomy and Motzer risk groups as stratification factors. No adjustment for multiplicity was performed. Results: On multivariable analysis, the onlymarker predictive of PFS independent of treatment was HGF, while IL-6 had an interaction with treatment (p-value for interaction = 0.02). None of the markers tested were predictive or prognostic of OS. Conclusions: Expression of HGF in pre-treatment specimens was prognostic for PFS in RCC patients and IL-6 was predictive of PFS in Bev treated patients, consistent with our findings in plasma. If validated, these data suggest that IL-6 may help guide use of anti-VEGF based therapies. Median PFS (months) HR (95% CI) p-value HGF Expression 1.4 (1.1-1.8) 0.02 Low (<= 4.03) 7.1 High (> 4.03 ) 5.7 IL-6 Expression 2.6 (1.2-6.1)* 0.02* IFN arm Low (<= 24.66) 4.1 0.4 (0.2-0.8)** High (> 24.66) 5.4 Bev+IFN arm Low (≤24.66) 10.6 1.3 (0.7-2.5)** High (> 24.66) 8.0 *Based on the interaction term; ** Within arm estimates.
A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP)
Authors: K. Reich, I. Zschocke, H. Bachelez, E.M.G.J. de Jong, P. Gisondi, L. Puig, R.B. Warren, C. Ortland, U. Mrowietz
Journal: British Journal of Dermatology (2017)

Around two-thirds of patients with psoriasis do not adhere to topical treatment. The Topical Treatment Optimization Programme (TTOP), a five-element tool, includes guidance for the conversation between dermatologists/nurses and patients, patient information material, telephone/e-mail helpdesks and treatment reminders. It has been developed by patients and dermatologists to help increase adherence to treatment in psoriasis.To compare TTOP with standard of care ('non-TTOP') within a large European investigator-initiated study, PSO-TOP (clinicaltrials.gov NCT01587755).Patients with mild-to-moderate psoriasis received calcipotriol/betamethasone dipropionate gel as standardized study medication and were randomized 1 : 1 to either TTOP or non-TTOP management. Study medication was applied once daily for 8 weeks followed by 'as needed' application for an additional 56 weeks. Response was defined as a Physician's Global Assessment (PGA) of 'clear' or 'almost clear'.In 1790 patients (full analysis set), response rates after 8 weeks (primary objective) were significantly higher for TTOP (36·3%) than for non-TTOP (31·3%, P = 0·0267). Better clinical outcome was accompanied by higher rates of patients feeling well informed about their skin condition, treatment and other factors related to adherence, but the Dermatology Life Quality Index was not statistically different. TTOP patients regarded the structured one-to-one conversations with their dermatologist/nurse as the most important element of TTOP.Patients randomized to the TTOP intervention had a better clinical response than patients receiving standard of care. Improved communication between the healthcare provider and patient might be an important element in increasing adherence to topical therapy in psoriasis.